We investigated the prognostic value of combined NfL and GFAP for McDonald 2024 MS diagnosis after CIS and associations with key genetic and environmental risk factors.<h4>Methods</h4>CIS participants, within six months after symptom onset, were included in a prospective cohort. The gene discussed is GFAP; the disease is myeloid sarcoma.